P. Barragan

发表

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

P. Serruys, G. Schuler, M. Morice, 2002, The New England journal of medicine.

Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients nonresistant to aspirin : ITALIC , a randomized multicenter trial Running title : ITALIC : 6 versus 24 month DAPT

J. Wójcik, M. Morice, P. Barragan, 2014 .

Clopidogrel Response Variability: Etiology and Clinical Relevance

G. Lemesle, P. Barragan, L. Bonello, 2015, Current Cardiovascular Risk Reports.

Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.

P. Barragan, L. Bonello, F. Paganelli, 2010, Journal of the American College of Cardiology.

Leaflet stress quantification of porcine vs bovine surgical bioprostheses: an in vitro study

P. Pibarot, P. Barragan, L. Thollon, 2021, Computer methods in biomechanics and biomedical engineering.

Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.

R. Whitbourn, N. Weissman, R. Stables, 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).

J. Wójcik, M. Morice, P. Barragan, 2017, JACC. Cardiovascular interventions.

Cyclosporine before PCI in Patients with Acute Myocardial Infarction.

N. Mewton, G. Rioufol, J. Dubois-Randé, 2015, The New England journal of medicine.

Treatment of drug-eluting stents in-stent restenosis with paclitaxel-coated balloon angioplasty: Insights from the French "real-world" prospective GARO Registry.

P. Barragan, V. Auffret, M. Bedossa, 2016, International journal of cardiology.

First-in-Man trial of a drug-free bioresorbable stent designed to minimize the duration of coronary artery scaffolding

J. Fajadet, P. Barragan, D. Carrié, 2021, Journal of biomaterials science. Polymer edition.

Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction

P. Barragan, L. Jacquin, L. Bonello, 2012, Thrombosis and Haemostasis.

Effect and Safety of Morphine Use in Acute Anterior ST‐Segment Elevation Myocardial Infarction

N. Mewton, G. Rioufol, J. Dubois-Randé, 2018, Journal of the American Heart Association.

SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study.

P. Barragan, G. Cassel, J. Wöhrle, 2012, Journal of the American College of Cardiology.

Presentation and revascularization patterns of patients admitted for acute coronary syndromes in France between 2004 and 2008 (from the National Observational Study of Diagnostic and Interventional Cardiac Catheterization [ONACI]).

X. Jouven, P. Barragan, C. Vassanelli, 2014, The American journal of cardiology.

Effects of Abciximab on the Architecture of Platelet-Rich Clots in Patients With Acute Myocardial Infarction Undergoing Primary Coronary Intervention

J. Soria, C. Soria, P. Barragan, 2001, Circulation.

210-Day follow-up of the RAVEL study: a randomized study with the sirolimus-eluting Bx VELOCITY™ balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions

P. Serruys, G. Schuler, C. Bode, 2002 .

Personalized antiplatelet therapy for coronary artery disease patients: is this the future?

G. Lemesle, P. Barragan, L. Bonello, 2009, Expert review of cardiovascular therapy.

Rationale and design of the Cyclosporine to ImpRove Clinical oUtcome in ST-elevation myocardial infarction patients (the CIRCUS trial).

N. Mewton, G. Rioufol, J. Dubois-Randé, 2015, American heart journal.

Platelet reactivity monitoring of clopidogrel loading dose in Unprotected Left Main Coronary Artery Stenting

P. Barragan, 2016 .

Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention.

G. Lemesle, P. Barragan, L. Bonello, 2010, Thrombosis research.

Emergence of the concept of platelet reactivity monitoring of response to thienopyridines

G. Lemesle, A. Pichard, P. Barragan, 2009, Heart.

Primary stenting with abciximab in acute myocardial infarction complicated by cardiogenic shock (the ADMIRAL trial)

P. Barragan, G. Montalescot, F. Paganelli, 2002 .

Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events

P. Auquier, P. Barragan, L. Bonello, 2007, Journal of thrombosis and haemostasis : JTH.

TCT-173 Safety and Clinical Performance of the Drug Eluting Osiro Stent in the Treatment of Subjects With Single De Novo Coronary Artery Lesions-II (BIOFLOW-II)

K. Stangl, F. Neumann, S. Cook, 2013 .

Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial.

R. V. van Geuns, P. Barragan, K. Oldroyd, 2022, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Discordant Grading of Aortic Stenosis Severity: New Insights from an In Vitro Study

P. Pibarot, P. Barragan, J. Adda, 2019, Structural Heart.

[Rotablator and endoprosthesis on the left main coronary trunk].

P. Barragan, L. Chaix, J. Camilleri, 1995, Archives des maladies du coeur et des vaisseaux.

Comparison of twelve-month outcomes after percutanous coronary intervention with everolimus-eluting versus zotarolimus-eluting or sirolimus-eluting stents from the PROENCY (PROmus ENdeavor CYpher) registry.

P. Damman, J. Tijssen, P. Barragan, 2012, The Journal of invasive cardiology.

Acute Gain in Minimal Lumen Area Following Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds or Xience Metallic Stents: Intravascular Ultrasound Assessment From the ABSORB II Trial.

P. Serruys, J. Tijssen, R. D. de Winter, 2015, JACC. Cardiovascular interventions.

Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent: 5-Year Outcomes of the Randomized BIOFLOW-II Trial.

K. Stangl, F. Neumann, S. Cook, 2018, JACC. Cardiovascular interventions.

741-3 Prevention of Subacute Occlusion After Coronary Stenting with Ticlopidine Regimen without Intravascular Ultrasound Guided Stenting

P. Barragan, J. Bouvier, J. Sainsous, 1995 .

HOW TO MANAGE PATIENTS WITH LOW RESPONSE TO CLOPIDOGREL Clopidogrel dosage The Intracoronary Stenting and Antithrombotic Regimen : Choose Between 3 High Oral Doses

G. Lemesle, A. Pichard, P. Barragan, 2009 .

Two strategies of clopidogrel loading dose to decrease the frequency of clopidogrel resistance in patients undergoing percutaneous coronary intervention.

P. Barragan, L. Bonello, F. Paganelli, 2008, Thrombosis research.

Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y12 inhibition

P. Barragan, Shinji Yamaguchi, J. Jakubowski, 2011, Thrombosis and Haemostasis.

A paradigm shift in anti-platelet therapy?

P. Barragan, L. Bonello, F. Paganelli, 2008, Platelets.

CRT-156 Two Year Safety And Clinical Performance Of The Drug Eluting Orsiro Stent In The Treatment Of Subjects With Single De Novo Coronary Artery Lesions (BIOFLOW-II)

K. Stangl, F. Neumann, S. Windecker, 2015 .

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.

P. Barragan, L. Bonello, F. Paganelli, 2008, Journal of the American College of Cardiology.

Retrograde left main stenting.

P. Barragan, P. Parikh, J. Bouvier, 1996, Catheterization and cardiovascular diagnosis.

Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent.

P. Barragan, Thierry Corcos, X. Favereau, 1999, The Journal of invasive cardiology.

Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis.

Françoise Dignat-George, P. Barragan, L. Bonello, 2009, The American journal of cardiology.

CORONARY ARTERY DISEASE Original Studies Resistance to Thienopyridines: Clinical Detection of Coronary Stent Thrombosis by Monitoring of Vasodilator-Stimulated Phosphoprotein Phosphorylation

U. Walter, P. Barragan, P. Commeau, 2003 .

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction

P. Barragan, G. Montalescot, Gilles Montalescot, 2001 .

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.

M. Morice, P. Barragan, G. Montalescot, 2001, The New England journal of medicine.

Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Coronary Stents: Three-Year Results of the RAVEL Trial

P. Serruys, G. Schuler, C. Bode, 2005, Circulation.

Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures.

P. Barragan, J. Bouvier, J. Sainsous, 2000, Journal of the American College of Cardiology.

Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting.

P. Barragan, Bouvier Jl, J. Bouvier, 1994, Catheterization and cardiovascular diagnosis.

Early versus late coronary stenting following acute myocardial infarction: results of the STENTIM I Study (French Registry of Stenting in Acute Myocardial Infarction).

A. Cribier, M. Morice, P. Barragan, 1997, Catheterization and cardiovascular diagnosis.

Coronary artery stenting without anticoagulation, aspirin, ultrasound guidance, or high balloon pressure: prospective study of 1,051 consecutive patients.

P. Barragan, J. Bouvier, J. Sainsous, 1997, Catheterization and cardiovascular diagnosis.

Cardioprotective effect of intracoronary nifedipine during percutaneous transluminal coronary angioplasty. A French double-blind cross-over multicentre study.

P. Barragan, M. Bertrand, N. Danchin, 1993, International journal of cardiology.

Three-dimensional numerical simulations of physiological flows in a stented coronary bifurcation

V. Deplano, P. Barragan, C. Bertolotti, 2004, Medical and Biological Engineering and Computing.

6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.

J. Wójcik, M. Morice, P. Barragan, 2015, Journal of the American College of Cardiology.

Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial

J. Wójcik, M. Morice, P. Barragan, 2014 .

Elastic recoil of coronary stents: A comparative analysis

P. Barragan, R. Rieu, J. Sainsous, 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Randomised comparison of coronary stenting with and without balloon predilatation in selected patients

C. Leclercq, P. Barragan, B. Moquet, 2001, Heart.

Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity

P. Barragan, L. Bonello, F. Paganelli, 2010, Thrombosis and Haemostasis.

Clinical outcomes after unprotected left main coronary artery occlusion: A retrospective multicentre cohort analysis

S. Cook, P. Barragan, M. Bedossa, 2023, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

ISR II study: A long‐term evaluation of sirolimus‐eluting stent in the treatment of patients with in‐stent restenotic native coronary artery lesions

P. Barragan, P. Commeau, J. Siméoni, 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent: Results of the Randomized BIOFLOW-II Trial

K. Stangl, F. Neumann, S. Cook, 2015, Circulation. Cardiovascular interventions.

Prognostic Value of Corrected QT-Interval Prolongation in Patients With Unstable Angina Pectoris

N. Weissman, G. Finet, R. Mehran, 2003 .

Sirolimus for below the knee lesions: Mid‐term results of SiroBTK study

P. Barragan, P. Commeau, P. Roquebert, 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial.

Patrick W Serruys, Eduardo Sousa, Laura Mauri, 2007, Journal of the American College of Cardiology.

Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.

P. Barragan, N. Lévy, L. Maillard, 2009, The American journal of cardiology.

Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents.

Bernard Chevalier, Yuki Katagiri, Yoshinobu Onuma, 2017, Journal of the American College of Cardiology.

Elective implantation of sirolimus-eluting stents for bifurcated and non-bifurcated unprotected left main coronary artery lesions: clinical outcomes at one year.

P. Serruys, S. Cook, J. Fajadet, 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

French Ministry of Health prospective multicentre study using bio-active stents coated with titanium nitride oxide: the EVIDENCE registry.

G. Finet, M. Morice, J. Fajadet, 2012, Archives of cardiovascular diseases.

Effects of Hemodynamic Conditions and Valve Sizing on Leaflet Bending Stress in Self-Expanding Transcatheter Aortic Valve: An In-vitro Study.

P. Pibarot, P. Barragan, L. Kadem, 2020, Artificial organs.

Radial force of coronary stents: A comparative analysis

Catherine Masson, Jean Fuseri, Vincent Garitey, 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Longitudinal compression behaviour of coronary stents: a bench-top comparative study.

P. Barragan, R. Rieu, V. Garitey, 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Effect of size and position of self-expanding transcatheter valve on haemodynamics following valve-in-valve procedure in small surgical bioprostheses: an in vitro study.

P. Pibarot, P. Barragan, J. Rodés‐Cabau, 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Assessment of the trackability, flexibility, and conformability of coronary stents: A comparative analysis

Régis Rieu, Jean Fuseri, Vincent Garitey, 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.

R. Whitbourn, N. Weissman, R. Stables, 2013, EuroIntervention.

Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicenter IDEAL-LM trial.

R. V. van Geuns, P. Barragan, K. Oldroyd, 2017, American heart journal.

[Recommendations of the French Cardiac Society concerning the education of physicians performing coronarography and angioplasty, organization and equipment of coronarography and coronary angioplasty centers].

J. Fajadet, P. Barragan, P. Steg, 2000, Archives des maladies du coeur et des vaisseaux.

CORONARY ARTERY DISEASE Original Studies Resistance to Thienopyridines: Clinical Detection of Coronary Stent Thrombosis by Monitoring of Vasodilator-Stimulated Phosphoprotein Phosphorylation

P. Barragan, P. Commeau, A. Lafont, 2003 .